Endophthalmitis Cultures (PROSPER)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01496794|
Recruitment Status : Terminated (poor enrollment)
First Posted : December 21, 2011
Last Update Posted : February 23, 2017
The intent of this surveillance study will be to obtain written permission from patients with bacterial endophthalmitis in order to compare sterilization rates of their cultured bacterial isolates to standard therapy (vancomycin and ceftazidime) versus combination therapy with vancomycin, ceftazidime, and moxifloxacin.
- Cultured bacterial isolates will demonstrate faster in vitro sterilization rates with combination treatment (vancomycin, ceftazidime, and moxifloxacin) compared to "standard therapy" with vancomycin and ceftazidime.
- Longitudinal analysis of resistance patterns of cultured isolates will show increasing rates of multi-antibiotic resistance.
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||3 participants|
|Official Title:||Prospective Surveillance of Patients With Endophthalmitis for Multi-antibiotic Resistance (PROSPER) Study|
|Study Start Date :||October 2011|
|Actual Primary Completion Date :||April 2016|
|Actual Study Completion Date :||April 2016|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01496794
|United States, Tennessee|
|Vanderbilt Eye Institute|
|Nashville, Tennessee, United States, 37232|
|Principal Investigator:||Stephen J Kim, MD||Vanderbilt University Medical Center|